Toxikon in the News

“Rapid Method for Microbiological Quality Control to Obtain Same Day Results: a Validation Approach”

In chapter 14 of “Encyclopedia of Rapid Microbiological Methods”, vol 4, Ir Peter Cornelis presents a validation approach for the approval of a rapid sterility test for batch release that can provide same day results. The technology described in this article is based on fluorescent viability staining and detection by solid phase cytometry (ChemScan®). A method that returns sterility test results within four hours will give a manufacturer superior production control and reduces production costs significantly.

The article gives an overview of our validation strategy and comparability between the traditional and alternative test. Additional considerations are discussed, including the use of stressed cells and matrix effects on the overall validation plan.

Ir Peter Cornelis is Department Supervisor at Toxikon Europe nv. He is responsible for the daily routine in the Microbiological laboratory. Furthermore, Peter Cornelis is involved in developing and validating new microbiological methods.

Peter Cornelis “Rapid Method for Microbiological Quality Control to Obtain Same Day Results: a Validation Approach” - Encyclopedia of Rapid Microbiological Methods, vol 4. Editor Michael Miller 2013, pg 315 – 327


Toxikon’s CEO Discusses Pharmacogenomics with Drug Discovery News

Dr. Laxman Desai, president and CEO of Toxikon Corp., discusses trends in cancer research in the September 2010 issue of Drug Discovery News.

In the Special Report, "Pharmacogenomics harnesses power of prediction, personalization," Dr. Desai says that while it is still in its infancy; knowledge of pharmacogenomics is increasing rapidly.

"Life science industries continue to delve into it and develop gene expression profiles for different classes of chemical carcinogens and possibly mutagens," Dr. Desai says. "Pharmacogenomics is impacting in a good way because, at some point, we will be able to develop and direct new drugs in a more efficient and more personalized fashion when it comes to treating diseases, like cancer."

To read the article, follow this link to Drug Discovery News.

medical device, preclinical contract research, lab work, combination devices, animal models, cardiovascular, ocular, orthopedic and neurological devices, biocompatibility toxicity, sensitization, irritation, specialized imaging, measurement and monitoring equipment